SCHEMBL349798

SCHEMBL349798

CCOC(=O)N1CCN(c2ccc(C3(C(=O)N4CCC5(C4)OC(=O)c4ccccc45)CC3)cn2)CC1

nearest known ligand 0.63

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 17/20 0.63
CYP2D6 P10635 1/20 0.57
OPRD1 P41143 1/20 0.44
KCNH2 Q12809 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL349457 1.00 HSD11B1 (0.63) HSD11B1CYP2D6OPRD1KCNH2SMN1; SMN2
SCHEMBL349458 1.00 HSD11B1 (0.63) HSD11B1CYP2D6OPRD1KCNH2SMN1; SMN2
SCHEMBL349799 1.00 HSD11B1 (0.63) HSD11B1CYP2D6OPRD1KCNH2SMN1; SMN2
SCHEMBL349026 0.94 HSD11B1 (0.60) HSD11B1CYP2D6OPRD1KCNH2SMN1; SMN2
SCHEMBL351434 0.94 HSD11B1 (0.60) HSD11B1CYP2D6OPRD1KCNH2SMN1; SMN2
SCHEMBL1319975 0.94 HSD11B1 (0.60) HSD11B1CYP2D6OPRD1KCNH2SMN1; SMN2
SCHEMBL349027 0.94 HSD11B1 (0.60) HSD11B1CYP2D6OPRD1KCNH2SMN1; SMN2
SCHEMBL351345 0.92 HSD11B1 (0.59) HSD11B1CYP2D6
SCHEMBL351346 0.92 HSD11B1 (0.59) HSD11B1CYP2D6
SCHEMBL350407 0.92 HSD11B1 (0.59) HSD11B1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150329561-A1 Amido Compounds And Their Use As Pharmaceuticals INCYTE CORPORATION 2015-11-19 US claimed
US-9126927-B2 Amido compounds and their use as pharmaceuticals INCYTE HOLDINGS CORPORATION (US) 2015-09-08 US claimed
EP-1756063-B1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2015-07-08 EP claimed
US-20120015928-A1 Amido Compounds And Their Use As Pharmaceuticals INCYTE CORPORATION (US) 2012-01-19 US claimed
US-8058288-B2 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2011-11-15 US claimed
US-20100256114-A1 Amido Compounds And Their Use As Pharmaceuticals INCYTE CORPORATION (US) 2010-10-07 US claimed
US-7304081-B2 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2007-12-04 US claimed
US-20070179142-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-02 US claimed
US-20050282858-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-22 US claimed
EP-2963021-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Holdings Corporation (US) 2016-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256114-A1 Amido Compounds And Their Use As Pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885CYP2D6 358/4885OPRD1 399/4885
US-20050282858-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885CYP2D6 358/4885OPRD1 399/4885
US-20120015928-A1 Amido Compounds And Their Use As Pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885CYP2D6 358/4885OPRD1 399/4885
US-20150329561-A1 Amido Compounds And Their Use As Pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885CYP2D6 358/4885OPRD1 399/4885
US-20070179142-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885CYP2D6 358/4885OPRD1 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.